Royalty Pharma (RPRX) Citi's 2024 Global Healthcare Conference summary

Portfolio growth and business momentum

• Over 30 products added since 2020 IPO, with most assets still in growth phases and several new launches expected to drive top-line acceleration in 2025.

• Key growth drivers include Tremfya, Trelegy, Evrysdi, and new launches such as Voranigo, Yorvipath, Niktimvo, Rytelo, and Cobenfy.

• Existing portfolio staples like cystic fibrosis, Xtandi, and Erleada remain significant contributors.

• Synthetic royalty deals have increased, supporting commercial launches and diversifying capital sources.

• Deliberate expansion into gene therapy with first investment last year, maintaining a selective approach.

Policy, market, and capital allocation

• Limited exposure to IRA policy changes, with only a few products affected and minimal expected impact.

• No anticipated changes in tax position or significant impact from broader policy reforms.

• Capital deployment guidance increased to $10–12 billion over five years, with potential for further growth as business scales.

• Commitment to growing dividends mid-single digits and active share buyback program to return capital to shareholders.

• Priority remains reinvesting in new royalties, with a focus on high-quality assets and measured growth.

Investment process and strategy

• Investment process has evolved with expanded team and aggressive investment in commercial analytics and data resources.

• Focus on high-conviction, data-driven decisions, leveraging proprietary insights for differentiated views.

• No strict category focus; investments range from orphan to large-market assets, driven by opportunity and risk-return profile.

• Capital markets conditions have little direct effect on deal flow; innovation and aggregate capital needs are primary drivers.

• Synthetic royalties and serial partnerships with companies are key differentiators, supported by strong industry relationships.